Log In
Print this Print this

MEN1112, OBT357

  Manage Alerts
Collapse Summary General Information
Company Oxford BioTherapeutics Ltd.
DescriptionDefucosylated recombinant antibody
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat acute myelogenous leukemia (AML)
Regulatory Designation
PartnerMenarini Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today